Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 187

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Oral Bisphosphonate Use and Breast Cancer Incidence in Postmenopausal Women

Open access
Chlebowski, Rowan T., Chen, Zhao, Cauley, Jane A., Anderson, Garnet, Rodabough, Rebecca J., McTiernan, Anne, Lane, Dorothy S., Manson, JoAnn E., Snetselaar, Linda, Yasmeen, Shagufta, O'Sullivan, Mary Jo, Safford, Monika, Hendrix, Susan L., Wallace, Robert B.·2010·Journal of Clinical Oncology

Abstract

Purpose: Emerging clinical evidence suggests intravenous bisphosphonates may inhibit breast cancer while oral bisphosphonates have received limited evaluation regarding breast cancer influence. Patients and Methods: The association between oral bisphosphonate use and invasive breast cancer was examined in postmenopausal women enrolled onto the Women's Health Initiative (WHI). We compared a published hip fracture prediction model, which did not incorporate bone mineral density (BMD), with total hip BMD in 10,418 WHI participants who had both determinations. To adjust for potential BMD difference based on bisphosphonate use, the hip fracture prediction score was included in multivariant analyses as a BMD surrogate. Results: Of the 154,768 participants, 2,816 were oral bisphosphonate users at entry (90% alendronate, 10% etidronate). As calculated hip fracture risk score was significantly associated with both BMD (regression line = 0.79 to 0.0478 log predicted fracture; P < .001; r = 0.43) and breast cancer incidence (P = .03), this variable was incorporated into regression analyses to adjust for BMD difference between users and nonusers of bisphopshonate. After 7.8 mean years of follow-up (standard deviation, 1.7), invasive breast cancer incidence was lower in bisphosphonate users (hazard ratio [HR], 0.68; 95% CI, 0.52 to 0.88; P < .01) as was incidence of estrogen receptor (ER) –positive invasive cancers (HR, 0.70; 95% CI, 0.52 to 0.94, P = .02). A similar but not significant trend was seen for ER-negative invasive cancers. The incidence of ductal carcinoma in situ was higher in bisphosphonate users (HR, 1.58; 95% CI, 1.08 to 2.31; P = .02). Conclusion: Oral bisphosphonate use was associated with significantly lower invasive breast cancer incidence, suggesting bisphosphonates may have inhibiting effects on breast cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2010.28.2095

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 187

Metadata

Authors
Chlebowski, R. T., Chen, Z., Cauley, J. A., Anderson, G., Rodabough, R. J., McTiernan, A., Lane, D. S., Manson, J. E., Snetselaar, L., Yasmeen, S., O'Sullivan, M. J., Safford, M., Hendrix, S. L., & Wallace, R. B.
Venue
Journal of Clinical Oncology
Published
2010-08-01
Volume
28
Issue
22
Pages
3582-3590
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2104518011
Cited by
187
References
3
FWCI
14.67
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Oral Bisphosphonate Use and Breast Cancer Incidence in Postmenopausal Women. https://app.cochat.ai/papers/10.1200/jco.2010.28.2095
The paper
Chlebowski, R. T., Chen, Z., Cauley, J. A., Anderson, G., Rodabough, R. J., McTiernan, A., Lane, D. S., Manson, J. E., Snetselaar, L., Yasmeen, S., O'Sullivan, M. J., Safford, M., Hendrix, S. L., & Wallace, R. B. (2010). Oral Bisphosphonate Use and Breast Cancer Incidence in Postmenopausal Women. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2010.28.2095

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.